NASDAQ: PGNX       Progenics Pharmaceuticals
Last Price Today's Change   Day's Range   Trading Volume
5.76   -0.09 (1.54%)  5.72 - 5.90  310,200


Avg Volume (4 weeks):886,965
4 Weeks Range:4.74 - 6.22
4 Weeks Price Volatility (%):
52 Weeks Range:3.42 - 6.31
52 Weeks Price Volatility (%):
Average Price Target: 13.00
Price Target Upside/Downside: +7.24


No recent Headlines for this stock.

Business Background

Progenics Pharmaceuticals is an American biotechnology company. The company develops innovative medicines to treat cancer. Progenics Pharmaceuticals' portfolio includes AZEDRA (to treat malignant and/or recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

  Be the first to like this.


4308  3684  701  236 

Top 10 Active Counters
 CHK 0.70+0.01 
 EEM 43.13+0.34 
 AMD 38.56+0.21 
 SPY 311.79+2.24 
 ACB 2.73-0.56 
 AIHS 1.07+0.65 
 AMRN 24.02+2.53 
 FCEL 0.825-0.064 
 TVIX 7.12-0.71 
 UBER 26.79+0.80 
Partners & Brokers